coteauBeta Get App

DSGN

Design Therapeutics, Inc.
$10.49
-2.24% Oct 22 close
Healthcare CompareTechnicals
-5%+42%+89%+136%+183%Oct 2025Oct 2026Apr 2026
DSGNSPY
1W
+0.1%
1M
-20.3%
3M
-9.8%
6M
-17.9%
YTD
+11.8%
1Y
+89.7%

Live chart

Loading live chart…

What they do

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for DSGN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
Coteau Long Book
Not in the current book

News

More news
Nike downgraded, Airbnb upgraded: Wall Street's top analyst calls
The Fly · Oct 02
Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target
MT Newswires · Oct 02
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
GlobeNewswire · Sep 02
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
24/7 Wall St. · Aug 27
Design Therapeutics Q2 Net Loss Narrows
MT Newswires · Aug 03

Key stats

Market value$671.5M
P/E (next 12 months, estimated)-6.6
52-week range$5.28 – $17.25
Dividend yieldNo dividend
Analyst consensusStrong Buy (7)
Average analyst price target$21.71 (+107%)
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

Next report: 2026-11-05 · before open · EPS est -0.35
24-1125-0325-0525-0825-1126-0326-0426-08-0.350.00
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-03-0.34-0.32+7.1%
2026-04-28-0.33-0.29+13.2%
2026-03-09-0.35-0.27+23.7%
2025-11-05-0.34-0.30+12.6%
2025-08-07-0.32-0.34-6.2%
2025-05-07-0.28-0.31-10.7%
2025-03-10-0.27-0.24+10.0%
2024-11-07-0.24-0.23+5.5%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–
Rating changes
Initiated
2026-10-02 · Wells Fargo started covering DSGN at Overweight
Reiterated
2026-05-04 · Oppenheimer reiterated Outperform on DSGN
Initiated
2026-03-16 · Jefferies started covering DSGN at Buy
Reiterated
2026-03-10 · RBC Capital reiterated Outperform on DSGN
Initiated
2026-01-07 · Oppenheimer started covering DSGN at Outperform
Upgrade
2025-12-03 · Leerink Partners upgraded DSGN from Market Perform to Outperform

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-21 18:23:19 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

Beta 0.9 · Oct 21, 2026